Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug AMG 436 targets Hard-to-Treat cancers in early trial

NCT ID NCT07403721

Recruiting now Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Feb 14, 2026 · Last updated May 12, 2026 · Updated 9 times

Summary

This early-phase study tests a new drug called AMG 436, alone or with other cancer treatments, in people with advanced solid tumors that have specific genetic changes (MSI-H or dMMR). The main goals are to check the drug's safety and find the best dose. About 464 adults with these cancers are being recruited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC OR LOCALLY ADVANCED SOLID TUMORS WITH MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR MISMATCHED REPAIR DEFICIENCY (DMMR) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Aichi Cancer Center

    RECRUITING

    Nagoya, Aichi-ken, 464-8681, Japan

  • Calvary Mater Newcastle Hospital

    RECRUITING

    Waratah, New South Wales, 2298, Australia

  • National Cancer Center Hospital

    RECRUITING

    Chuo-ku, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East

    RECRUITING

    Kashiwa-shi, Chiba, 277-8577, Japan

  • Next Oncology - Dallas

    RECRUITING

    Irving, Texas, 75039, United States

  • Peter MacCallum Cancer Centre

    RECRUITING

    Melbourne, Victoria, 3000, Australia

  • The Cancer Institute Hospital of Japanese Foundation for Cancer Research

    RECRUITING

    Koto-ku, Tokyo, 135-8550, Japan

  • Zhongshan Hospital Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

Conditions

Explore the condition pages connected to this study.

METASTATIC OR LOCALLY ADVANCED SOLID TUMORS WITH MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR MISMATCHED REPAIR DEFICIENCY (DMMR)